# BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

> **NCT05474885** · PHASE1 · UNKNOWN · sponsor: **iCell Gene Therapeutics** · enrollment: 15 (estimated)

## Conditions studied

- Relapsed/Refractory, Systemic Lupus Erythematosus (SLE)

## Interventions

- **BIOLOGICAL:** BCMA-CD19 cCAR T cells

## Key facts

- **NCT ID:** NCT05474885
- **Lead sponsor:** iCell Gene Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-01
- **Primary completion:** 2025-04-30
- **Final completion:** 2025-04-30
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2022-07-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05474885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05474885, "BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05474885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*